| 129 | |
| Summary | Gut microbes (species: Lactobacillus reuteri) decrease Resveratrol 's toxicity. |
| Gut | |
| Resveratrol (PubChem CID: 445154) | |
| Lactobacillus reuteri (Tax ID: 1598) | |
| 33722710 | |
| decrease toxicity | |
| Resveratrol is a natural phenolic compound with anti-inflammatory properties. Resveratrol can reduce mortality of acute respiratory distress syndrome (ARDS) by attenuating Staphylococcal Enterotoxin B antigen. Staphylococcal Enterotoxin B induces inflammatory cytokines which result in 100% mortality in C3H/HeJ mice and increases pathogenic Proteobacteria phylum and Propionibacterium acnes species in the lungs. Treatment with resveratrol can attenuate Staphylococcal Enterotoxin B and increase probiotic Actinobacteria phylum, Tenericutes phylum, and Lactobacillus reuteri species in both the colon and lungs. Mice transplanted microbiota with L. reuterithen and injected with Staphylococcal Enterotoxin B then treated with resveratrol shows inhibition of production of pro-inflammatory cytokines as IFN-γ and IL-17 but increasing the anti-inflammatory IL-10. furthermore, decreasing lung infiltrate to mononuclear cells, cytotoxic CD8+ T cells, NKT cells, Th1 cells, and Th17 cells, but an increase in the population of regulatory T cells (Tregs) and Th3 cells, and increase in the survival of mice from SEB-mediated ARDS. |
Browse Drug-Microbiome Relationship
Home